| Patent application number | Description | Published |
|---|
| 20080306109 | Indolizine Derivatives as Ligands of the Crth2 Receptor - Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of, for example, asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis. Formula (I) wherein R | 12-11-2008 |
| 20080318913 | Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | 12-25-2008 |
| 20090093477 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY - Compounds of formula (I) and multimers thereof are inhibitors of human neutrophil elastase activity, and of utility in the treatment of, e.g., COPD: | 04-09-2009 |
| 20090105268 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors - A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases. | 04-23-2009 |
| 20090111795 | Multimers of Heterocyclic Compounds and Their Use - A compound of formula (I): M-L-M, wherein L is a linker and each M is independently a group of formula (II): is useful in therapy, e.g. of respiratory diseases. | 04-30-2009 |
| 20090156600 | Quinolines and Their Therapeutic Use - Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component; in which: R | 06-18-2009 |
| 20090163534 | Indolizine Derivatives - Compounds of formula (I) are ligands of the CRTH2 receptor and are useful in the treatment of respiratory disease: Formula (I) wherein R | 06-25-2009 |
| 20100010034 | CRTH2 ANTAGONISTS - The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-yl-methyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid. | 01-14-2010 |
| 20100056565 | Heterocyclic Derivatives as M3 Muscarinic Receptors - This invention relates to M3 antagonists of formula (I) wherein R | 03-04-2010 |
| 20100093751 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor - Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R | 04-15-2010 |
| 20100113540 | Azole and Thiazole Derivatives and Their Use - Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R | 05-06-2010 |
| 20100137300 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists - The specific compounds of this list: {7-cyano-2-methyl-1-[4-(morpholine-4-sutfonyl)benzyl]indolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro-4-(morpholine-4-sutfonyl)phenylsutfanyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl}acetic acid are ligands of the CRTH2 receptor and are useful in the treatment of respiratory diseases. | 06-03-2010 |
| 20100144786 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS - Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component. | 06-10-2010 |
| 20100144787 | Quinolines and Their Therapeutic Use - Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R | 06-10-2010 |
| 20100144852 | Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses - Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R | 06-10-2010 |
| 20110053986 | RESPIRATORY DISEASE TREATMENT - There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | 03-03-2011 |
| 20110060026 | Indoles Active on CRTH2 Receptor - Indole derivatives having therapeutic utility are of formula (I): X is —SO | 03-10-2011 |
| 20110071175 | Indoles and Their Therapeutic Use - Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO | 03-24-2011 |
